<DOC>
	<DOCNO>NCT01416870</DOCNO>
	<brief_summary>The purpose study investigate bioequivalence Bicalutamide new formation Casodex commercial tablet ( 80mg ) Japanese healthy male subject</brief_summary>
	<brief_title>Bioequivalence Bicalutamide New Formulation Japan</brief_title>
	<detailed_description>Bioequivalence study ICI176,334-1 ( Bicalutamide new formulation ) Japanese healthy male subject - evaluation bioequivalence ICI176,334-1 Casodex tablet ( 80mg )</detailed_description>
	<mesh_term>Bicalutamide</mesh_term>
	<criteria>Provision sign date , write informed consent prior study specific procedures Japanese healthy male subject age 20 45 year Male subject willing use barrier contraception ie , condom , 3 month last dose investigational product Have body mass index ( BMI ) 17 27 kg/m2 Eligible base physical finding , supine BP , pulse rate , ECG laboratory assessment , judge investigator ( ) Presence disease medical treatment History presence cardiovascular , respiratory , hepatic , renal , gastrointestinal , immunological , blood , endocrine , neurological mental disease interfere absorption , distribution , metabolism excretion drug judge investigator ( ) Presence infectious disease , bacteria , virus fungus Presence allergic disorder , asthma , pollen disease atopic dermatitis , judge necessary medical treatment Any large surgical history gastrointestinal tract gastric/intestinal resection suturation</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>safety</keyword>
	<keyword>bicalutamide</keyword>
	<keyword>Casodex</keyword>
	<keyword>Japanese</keyword>
	<keyword>healthy subject</keyword>
</DOC>